Treatment of severe coagulopathy after gunshot injury to the head using recombinant activated factor VII

Venkatesh Aiyagari, Jose A. Menendez, Michael N. Diringer

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Purpose: Patients with severe penetrating head injury often have a coagulopathy that is difficult to correct. In this report, we describe 3 such patients who were treated with activated factor VII (FVIIa) to stop ongoing hemorrhage that was refractory to conventional treatment. Subjects and Methods: We treated 3 patients with severe head injury secondary to gunshot wounds to the head. All 3 patients had ongoing bleeding secondary to a severe consumptive coagulopathy that was refractory to treatment with fresh frozen plasma, platelets, and cryoprecipitate. Recombinant FVIIa was then administered to achieve hemostasis. Results: Administration of FVIIa (90-120 μg/kg) was successful in rapidly achieving hemostasis and correcting abnormal laboratory parameters indicative of coagulopathy in all patients. Although all 3 patients died, control of bleeding made organ donation possible in 2 patients. Conclusion: In patients with a severe head injury and coagulopathy, use of FVIIa may help in correction of coagulopathy and decrease transfusion requirements. In patients where ongoing bleeding precludes the declaration of brain death, the use of this agent might help in achieving hemodynamic stability and preserve the possibility of organ donation. The ethical implications of using FVIIa in this situation are discussed.

Original languageEnglish (US)
Pages (from-to)176-179
Number of pages4
JournalJournal of Critical Care
Volume20
Issue number2
DOIs
StatePublished - Jun 2005

Fingerprint

Factor VIIa
Craniocerebral Trauma
Hemorrhage
Tissue and Organ Procurement
Therapeutics
Hemostasis
Penetrating Head Injuries
Gunshot Wounds
Brain Death
Blood Platelets
Hemodynamics
Head

Keywords

  • Coagulopathy
  • Factor VII
  • Head injury

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Treatment of severe coagulopathy after gunshot injury to the head using recombinant activated factor VII. / Aiyagari, Venkatesh; Menendez, Jose A.; Diringer, Michael N.

In: Journal of Critical Care, Vol. 20, No. 2, 06.2005, p. 176-179.

Research output: Contribution to journalArticle

@article{a9856138fd2e482db5ea2c46acde7dec,
title = "Treatment of severe coagulopathy after gunshot injury to the head using recombinant activated factor VII",
abstract = "Purpose: Patients with severe penetrating head injury often have a coagulopathy that is difficult to correct. In this report, we describe 3 such patients who were treated with activated factor VII (FVIIa) to stop ongoing hemorrhage that was refractory to conventional treatment. Subjects and Methods: We treated 3 patients with severe head injury secondary to gunshot wounds to the head. All 3 patients had ongoing bleeding secondary to a severe consumptive coagulopathy that was refractory to treatment with fresh frozen plasma, platelets, and cryoprecipitate. Recombinant FVIIa was then administered to achieve hemostasis. Results: Administration of FVIIa (90-120 μg/kg) was successful in rapidly achieving hemostasis and correcting abnormal laboratory parameters indicative of coagulopathy in all patients. Although all 3 patients died, control of bleeding made organ donation possible in 2 patients. Conclusion: In patients with a severe head injury and coagulopathy, use of FVIIa may help in correction of coagulopathy and decrease transfusion requirements. In patients where ongoing bleeding precludes the declaration of brain death, the use of this agent might help in achieving hemodynamic stability and preserve the possibility of organ donation. The ethical implications of using FVIIa in this situation are discussed.",
keywords = "Coagulopathy, Factor VII, Head injury",
author = "Venkatesh Aiyagari and Menendez, {Jose A.} and Diringer, {Michael N.}",
year = "2005",
month = "6",
doi = "10.1016/j.jcrc.2005.02.004",
language = "English (US)",
volume = "20",
pages = "176--179",
journal = "Journal of Critical Care",
issn = "0883-9441",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Treatment of severe coagulopathy after gunshot injury to the head using recombinant activated factor VII

AU - Aiyagari, Venkatesh

AU - Menendez, Jose A.

AU - Diringer, Michael N.

PY - 2005/6

Y1 - 2005/6

N2 - Purpose: Patients with severe penetrating head injury often have a coagulopathy that is difficult to correct. In this report, we describe 3 such patients who were treated with activated factor VII (FVIIa) to stop ongoing hemorrhage that was refractory to conventional treatment. Subjects and Methods: We treated 3 patients with severe head injury secondary to gunshot wounds to the head. All 3 patients had ongoing bleeding secondary to a severe consumptive coagulopathy that was refractory to treatment with fresh frozen plasma, platelets, and cryoprecipitate. Recombinant FVIIa was then administered to achieve hemostasis. Results: Administration of FVIIa (90-120 μg/kg) was successful in rapidly achieving hemostasis and correcting abnormal laboratory parameters indicative of coagulopathy in all patients. Although all 3 patients died, control of bleeding made organ donation possible in 2 patients. Conclusion: In patients with a severe head injury and coagulopathy, use of FVIIa may help in correction of coagulopathy and decrease transfusion requirements. In patients where ongoing bleeding precludes the declaration of brain death, the use of this agent might help in achieving hemodynamic stability and preserve the possibility of organ donation. The ethical implications of using FVIIa in this situation are discussed.

AB - Purpose: Patients with severe penetrating head injury often have a coagulopathy that is difficult to correct. In this report, we describe 3 such patients who were treated with activated factor VII (FVIIa) to stop ongoing hemorrhage that was refractory to conventional treatment. Subjects and Methods: We treated 3 patients with severe head injury secondary to gunshot wounds to the head. All 3 patients had ongoing bleeding secondary to a severe consumptive coagulopathy that was refractory to treatment with fresh frozen plasma, platelets, and cryoprecipitate. Recombinant FVIIa was then administered to achieve hemostasis. Results: Administration of FVIIa (90-120 μg/kg) was successful in rapidly achieving hemostasis and correcting abnormal laboratory parameters indicative of coagulopathy in all patients. Although all 3 patients died, control of bleeding made organ donation possible in 2 patients. Conclusion: In patients with a severe head injury and coagulopathy, use of FVIIa may help in correction of coagulopathy and decrease transfusion requirements. In patients where ongoing bleeding precludes the declaration of brain death, the use of this agent might help in achieving hemodynamic stability and preserve the possibility of organ donation. The ethical implications of using FVIIa in this situation are discussed.

KW - Coagulopathy

KW - Factor VII

KW - Head injury

UR - http://www.scopus.com/inward/record.url?scp=24044515511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24044515511&partnerID=8YFLogxK

U2 - 10.1016/j.jcrc.2005.02.004

DO - 10.1016/j.jcrc.2005.02.004

M3 - Article

VL - 20

SP - 176

EP - 179

JO - Journal of Critical Care

JF - Journal of Critical Care

SN - 0883-9441

IS - 2

ER -